Insulin Titration — Competitive Intelligence Brief

Insulin Titration (Insulin Titration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (dosing protocol). Area: Diabetes.

marketed Insulin (dosing protocol) Insulin receptor Diabetes Small molecule

Target snapshot

Insulin Titration (Insulin Titration) — Weill Medical College of Cornell University. Insulin titration is a dosing strategy that adjusts insulin administration based on blood glucose levels to achieve optimal glycemic control.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Titration TARGET	Insulin Titration	Weill Medical College of Cornell University	marketed	Insulin (dosing protocol)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (dosing protocol) class)

1. Weill Medical College of Cornell University · 1 drug in this class